Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.

Abstract

Tigecycline is a novel glycylcycline antibacterial agent discovered and developed by Wyeth Research. The U.S. Food and Drug Administration (FDA) recently approved the agent for use in patients with complicated skin infections, skin-structure infections and intra-abdominal infections. Tigecycline is currently under review by regulatory agencies worldwide. Global clinical trials are underway to further assess the efficacy of tigecycline for community- and hospital- acquired pneumonia. Because of the expanded broad spectrum of activity of tigecycline with proven utility against Gram-positive, Gram-negative, anaerobic and atypical pathogens in addition to resistant organisms of clinical importance--community- and hospital-acquired methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., penicillin-resistant Streptococcus pneumoniae and Escherichia coli and Klebsiella pneumoniae expressing extended-spectrum beta-lactamases--this novel antibiotic has come into clinical use at a critical time and will be a welcome asset to the current armamentarium.

• Authors: C Hal Jones, Peter J Petersen
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 41 Issue 10 Pg. 637-59 (Oct 2005) ISSN: 1699-3993 [Print] Spain
• PMID: 16389407 (Publication Type: Journal Article, Review)
• Copyright: Copyright (c) 2005 Prous Science. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Tetracyclines
• CL 331002
• Tigecycline
• Minocycline

Topics

• Animals
• Anti-Bacterial Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation, Preclinical (methods)
• Humans
• Microbial Sensitivity Tests
• Minocycline (analogs & derivatives, pharmacology, therapeutic use)
• Molecular Structure
• Tetracyclines (chemistry)
• Tigecycline